Loading quotes...
Forecast
The analysts' average price target is €14.06 (+49.57%). The median is €13.00 (+38.30%).
| Buy |
17 |
| Hold |
2 |
| Sell |
1 |
News Go to news feed
Alphatec Holdings: CEO purchase triggers short squeeze and stock rises about 20%
CEO Patrick Miles bought $1.01 million of his own shares near the 52-week low. High short interest led to covering, causing the stock to rise by nearly 20% on September 11, 2026 on increased volume. The company reports 15% revenue growth and positive free cash flow. » More on finanzen.net
Alphatec Holdings: CEO buy near 52-week low sends stock sharply higher
Alphatec Holdings' stock rose about 19% in afternoon trading after CEO Patrick Miles purchased 115,000 shares worth roughly $1.01 million at a weighted average price of $8.81. The purchase was made near the 52-week low and is seen as a strong insider vote of confidence, which, together with high short interest, contributed to a short squeeze. The company also recently reported a 15% revenue increase to $213.5 million, positive free cash flow, and reaffirmed its full-year guidance of around $882 million, while US markets overall showed a recovery. » More on de.investing.com
Alphatec confirms growth model and full-year targets at Wells Fargo conference
Alphatec said procedure volume was about 20% higher in the first half and reaffirmed its 2026 forecast of $882 million revenue, $140 million EBITDA and $20 million free cash flow. Management cited increasing surgeon adoption, EOS robotics, software and the Theradaptive acquisition as the main growth drivers, but acknowledged near-term pressure from lower revenue per procedure and reduced follow-up rates for biologics. For 2027 the company is targeting $1 billion in revenue, roughly 18% EBITDA margin and $65 million free cash flow, and sees further upside from margin improvements. Alphatec expects rising surgeon acceptance and product penetration to support long-term growth of 15–20% annually. » More on de.investing.com
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 187.08m | 18.84% |
| Gross profit | 135.02m | 23.27% |
| Net profit | -22.59m | 35.29% |
| EBITDA | 5.66m | 179.91% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.41bn |
Number of shares | 153.79m |
52-week high/low | €20.19 - €5.91 |
| Dividends | No |
Beta | 0.85 |
P/E ratio | -14.69 |
PEG ratio | -0.30 |
P/B ratio | -136.16 |
P/S ratio | 2.00 |
Company profile
Alphatec Holdings, Inc. ist ein Medizintechnikunternehmen, das Technologien für die chirurgische Behandlung von Wirbelsäulenerkrankungen konzipiert, entwickelt und vorantreibt. Das Unternehmen bietet das SafeOp Neural InformatiX System an, eine Alpha InformatiX Produktplattform, die das Risiko intraoperativer Nervenverletzungen verringert; das Sigma transforaminale lumbale interkorporelle Fusion pedikelbasiertes Zugangssystem, das eine direkte Visualisierung anatomischer Orientierungspunkte ermöglicht; Sigma PTP Zugangs- und Patientenpositionierungssystem; Squadron lateraler Retraktor zur Maximierung der Patientenergebnisse; Invictus Spinal Fixation System, ein thorakolumbales Fixationssystem zur Behandlung einer Reihe von Pathologien; und Invictus MIS SingleStep System, das eine minimalinvasive Platzierung von Pedikelschrauben ermöglicht. Darüber hinaus bietet das Unternehmen das Invictus Modular Fixation System an, das die Anpassungsfähigkeit durch die Modularität der Schrauben erhöht; das OsseoScrew System zur Wiederherstellung der Integrität der Wirbelsäule; das Arsenal spinal fixation system, eine umfassende thorakolumbale Fixationsplattform zur Behandlung einer Reihe von degenerativen bis deformierenden Pathologien und chirurgischen Verfahren; Aspida Anteriores lumbales Plattensystem, ein Fixationssystem für die anteriore lumbale interkorporelle Fusion; AMP Anti-Migrationsplatte; OCT Wirbelsäulenfixationssystem; trestle luxe anteriores zervikales Plattensystem; und Insignia Anteriores zervikales Plattensystem. Darüber hinaus bietet das Unternehmen die Implantate IdentiTi Porous Ti, Transcend Lateral und Battalion Posterior Interbody Implants sowie Biologika bestehend aus Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix und Amnioshield Amniotic Tissue Barrier sowie EOS Imaging Products an. Das Unternehmen vertreibt seine Produkte über ein Netz unabhängiger Vertriebshändler und direkter Handelsvertreter in den Vereinigten Staaten. Das Unternehmen wurde 1990 gegründet und hat seinen Hauptsitz in Carlsbad, Kalifornien.
| Name | ALPHATEC HOLDINGS INC. |
| CEO | Patrick S. Miles |
| Headquarters | Carlsbad,
ca USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 12/06/2006 |
| Employees | 913 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ATEC |
Frankfurt | L1Z1.F |
Düsseldorf | L1Z1.DU |
München | L1Z1.MU |